Study finds most patients with multisystem inflammatory syndrome in children (MIS-C) fully recover
1. In this single-center study of children hospitalized with MIS-C, most had complete recovery of cardiac function.
2. While most markers of inflammation normalized...
Platelet-rich plasma injection does not significantly improve chronic midportion Achilles tendinopathy outcomes
1. The clinical outcome of chronic midportion Achilles tendinopathy, measured via the Victorian Institute of Sport Assessment-Achilles score, did not differ between participants randomized...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the placebo group.
2. The proportion...
Rituximab increases sustained complete remission in patients with pemphigus vulgaris
1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus vulgaris.
2. Patients treated with...
Ziltivekimab antagonism of IL-6 reduces inflammation and thrombosis in patients with atherosclerotic risk factors
1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner.
2. Thrombotic biomarkers including fibrinogen, serum amyloid...
Voclosporin shows clinical promise for treatment of active lupus nephritis
1. A significantly greater proportion of patients in the voclosporin group achieved complete renal responses after 52 weeks compared to the placebo group.
2. The...
Reduced-dose glucocorticoid adjunct non-inferior to high-dose glucocorticoid plus rituximab regimen for induction of disease...
1. Reduced-dose glucocorticoid plus rituximab regimen was non-inferior compared to high-dose glucocorticoid plus rituximab regimen for induction of disease remission in ANCA-associated vasculitis
Evidence Rating...
Cardiovascular safety of hydroxychloroquine in veterans with rheumatoid arthritis
1. Among a large, matched cohort of veterans with rheumatoid arthritis, initiation of hydroxychloroquine was not associated with a higher risk of adverse cardiovascular...
Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab.
2. High-dose upadacitinib was associated with more frequent...
Bimekizumab superior to secukinumab for plaque psoriasis treatment
1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment.
2. Bimekizumab treatment was...
